Form 4: CG Oncology Director James Mulay Acquires Stock Options
SEC Form 4 Filing
Director James Mulay acquired stock options in CG Oncology, Inc. on October 4, 2024.
Summary
- James Mulay, a director of CG Oncology, Inc., reported a transaction involving stock options.
- On October 4, 2024, Mulay acquired options to purchase 15,600 shares of CG Oncology's common stock at an exercise price of $36.63.
- The options vest monthly over a year, starting from the grant date, contingent upon continuous service to the issuer.
- Following the transaction, Mulay directly owns 15,600 derivative securities.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding stock option grants, indicating a neutral sentiment.
Industry Context
This is a standard Form 4 filing, reflecting a change in beneficial ownership by a company insider. It's common for directors and officers to receive stock options as part of their compensation.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment as it aligns the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 10/04/2024 | Date of stock option grant and transaction. |
| 10/04/2024 | Vesting start date for the stock options. |
| 10/03/2034 | Expiration date of the stock options. |
| 10/07/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.